




Instance: composition-en-3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: CompositionUvEpi
Title: "Composition for scintimun Package Leaflet"
Description:  "Composition for scintimun Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa9ec64f13568156fa1a6ff3b0e61aebc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - scintimun"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Scintimun is and what it is used for  </li>
<li>What you need to know before you are given Scintimun </li>
<li>How Scintimun is given </li>
<li>Possible side effects  </li>
<li>How Scintimun is stored </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What scintimun is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What scintimun is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Scintimun is a medicine containing an antibody (besilesomab) used to target specific cells called 
granulocytes (a type of white blood cells involved in the inflammation process) in your body. 
Scintimun is used for the preparation of a radioactive solution for injection of technetium(99mTc)-
besilesomab. Technetium(99mTc) is a radioactive element allowing the organs where besilesomab 
accumulates to be seen using a special camera. </p>
<p>This medicine is a radiopharmaceutical product for diagnostic use only in adults. 
After injection into your vein, your doctor can obtain pictures (scans) of your organs that give more 
information about the detection of sites of inflammation and/or infection. However Scintimun should 
not be used for the diagnosis of diabetic foot infection. 
The use of Scintimun does involve exposure to small amounts of radioactivity. Your doctor and the 
nuclear medicine doctor have considered that the clinical benefit that you will obtain from the 
procedure with the radiopharmaceutical outweights the risk due to radiation. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Scintimun must not be used:</p>
<ul>
<li>if you are allergic to besilesomab, to antibody from mouse origin or any other antibodies, or to 
sodium pertechnetate (99mTc) solution or any of the other ingredients of this medicine (listed in 
section 6). </li>
<li>if you have a positive response to a test detecting human anti-mouse antibodies (HAMA test). 
Ask your doctor if you are not sure. </li>
<li>if you are pregnant. </li>
</ul>
<p>Warnings and precautions<br />
Talk to the nuclear medicine specialist before using Scintimun:</p>
<ul>
<li>if you have previously been administered Scintimun, because you should only be administered 
Scintimun once in your lifetime. If you are not sure if you have been given this medicine before, 
please let your doctor know. </li>
<li>if you have had a scintigraphy with technetium in the last 2 days. </li>
<li>if you have a tumoral pathology involving a secretion of carcino-embryonic antigen (CEA) 
which could interfere with this investigation. </li>
<li>if you have any blood disease. </li>
<li>if you are breast-feeding. </li>
</ul>
<p>Before administration of Scintimun 
In order to obtain images of best quality and to reduce the radiation exposure of your bladder, you 
should drink sufficient amounts and empty your bladder prior to and after the scintigraphic 
examination. </p>
<p>Children and adolescents 
This medicine is not recommended for use in patients below 18 years of age because the safety and 
efficacy of the product have not been established. </p>
<p>Other medicines and Scintimun 
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other 
medicines, including medicines obtained without a prescription, since they may interfere with the 
interpretation of the images. 
Medicines reducing inflammation and medicines affecting the production of your blood cells (such as 
corticosteroids or antibiotics) may affect the results of your examination. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your nuclear medicine doctor for advice before you are given this medicine.  </p>
<p>You must inform the nuclear medicine doctor before the administration of Scintimun if there is a 
possibility you might be pregnant, if you have missed your period or if you are breast-feeding. When 
in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure. </p>
<p>If you are pregnant you must not be given Scintimun. 
Investigations in nuclear medicine may involve a risk to the unborn. </p>
<p>If you are breast-feeding you must stop breast-feeding for 3 days after your injection and the expressed 
milk should be discarded. If you wish, you can express and store your breast milk before your 
injection. This will protect your child from the radiation that may be present in your breast milk. 
Please ask your nuclear medicine doctor when you can resume breast-feeding. 
Moreover you must avoid close contact with your child during the first 12 hours after the injection. </p>
<p>Driving and using machines 
It is considered unlikely that Scintimun will affect your ability to drive or to use machines. </p>
<p>Scintimun contains sorbitol and sodium 
This medicine contains 2 mg sorbitol in each vial of Scintimun. Sorbitol is a source of fructose. If you 
have hereditary fructose intolerance (HFI), a rare genetic disorder, you must not receive this medicine. 
Patients with HFI cannot break down fructose, which may cause serious side effects.<br />
You must tell your doctor before receiving this medicine if you  have HFI. </p>
<p>This medicine contains less than 1 mmol of sodium (23 mg) per vial, that is to say essentially  sodium- free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of radiopharmaceutical products. Scintimun 
will only be used in special controlled areas. This product will only be handled and given to you by 
people who are trained and qualified to use it safely. These persons will take special care for the safe 
use of this product and will keep you informed of their actions. </p>
<p>The nuclear medicine doctor supervising the procedure will decide on the quantity of 
technetium(99mTc)- besilesomab to be used in your case. It will be the smallest quantity necessary to 
get the desired information.<br />
The quantity to be administered usually recommended for an adult ranges from 400 to 800 MBq 
(megabecquerel, the unit used to express radioactivity).  </p>
<p>Administration of Scintimun and conduct of the procedure 
Scintimun is administered intravenously. 
A single injection into a vein in your arm is sufficient to conduct the test your doctor needs. </p>
<p>Duration of the procedure 
Your Nuclear medicine doctor will inform you about the usual duration of the procedure.  </p>
<p>After administration of Scintimun 
Because you could emit radiation especially harmful to young children during the first 12 hours after 
the injection, you should avoid close contact with young children and pregnant women during this 
period of time. </p>
<p>The nuclear medicine doctor will inform you if you need to take any special precautions after 
receiving this medicine. Contact your nuclear medicine doctor if you have any questions. </p>
<p>If you have been given more Scintimun than you should 
An overdose is unlikely because injection is prepared as a single dose by the hospital personnel, under 
strictly controlled conditions. However, in the case of an overdose, you will be asked to drink plenty 
of water and to take laxatives to increase the elimination of the product from your body. </p>
<p>Should you have any further questions on the use of Scintimun, please ask the nuclear medicine doctor 
who supervises the procedure. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk 
of cancer and hereditary abnormalities. </p>
<p>About 14 out of 100 patients having this injection have been found to produce antibodies in their 
blood reacting against the antibody present in Scintimun. This may increase the risk of allergic 
reactions in case of repeated administration of Scintimun. Therefore you should not receive Scintimun 
a second time. 
In case of allergic reaction you will receive appropriate treatment from your doctor. </p>
<p>Possible side effects are listed in the order of their frequency below: </p>
<p>Very common (may affect more than 1 in 10 people): 
Development of human anti-mouse antibodies reacting against the antibody in Scintimun 
(antibody of the mouse cells) with a risk of allergic reaction </p>
<p>Common (may affect up to 1 in 10 people): 
Low blood pressure </p>
<p>Uncommon (may affect up to 1 in 100 people): 
Allergic reaction, including swelling of the face, hives (urticaria) </p>
<p>Rare (may affect up to 1 in 1,000 people): 
* Serious allergic reaction which causes difficulty in breathing or dizziness 
* Muscle or joint pain </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or the specialist in nuclear medicine. This includes any 
possible side effects not listed in this leaflet. You can also report side effects directly via the national 
reporting system listed in Appendix V. By reporting side effects you can help provide more 
information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored under the responsibility of the 
specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national 
regulation on radioactive materials. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Scintimun contains 
- The active substance is besilesomab (anti-granulocyte monoclonal antibody from mouse 
origin).  </p>
<p>One vial of Scintimun contains 1 mg of besilesomab. 
- The other ingredients are (see section 2  Scintimun contains sorbitol and sodium ): </p>
<p>Scintimun </p>
<p>Sodium dihydrogen phosphate, anhydrous </p>
<p>Disodium monohydrogen phosphate, anhydrous </p>
<p>Sorbitol EUnder nitrogen atmosphere </p>
<p>Solvent for Scintimun </p>
<p>1, 1, 3, 3-propane tetraphosphonic acid, tetrasodium salt, dihydrate (PTP) </p>
<p>Stannous chloride dihydrate </p>
<p>Sodium hydroxide / Hydrochloric acid  </p>
<p>Nitrogen </p>
<p>What Scintimun looks like and contents of the pack 
Scintimun is a kit for radioactive preparation. 
The vial of Scintimun contains a white powder.<br />
The vial of solvent for Scintimun contains a white powder. </p>
<p>The kit contains one or two multidose vials of Scintimun with one or two vials of solvent. </p>
<p>Not all pack-sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
CIS bio international 
B.P. F-91192 Gif-sur-Yvette Cedex 
France </p>
<p>This leaflet was last revised in {MM/YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: CompositionUvEpi
Title: "Composition for scintimun Package Leaflet"
Description:  "Composition for scintimun Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa9ec64f13568156fa1a6ff3b0e61aebc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - scintimun"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal De vide, før De får Scintimun 
3. Sådan får De Scintimun 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What scintimun is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What scintimun is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Scintimun er et lægemiddel, der indeholder et antistof (besilesomab), som er målrettet mod specifikke 
celler i kroppen, som kaldes granulocytter (en type hvide blodlegemer, der er involveret i 
betændelsesprocessen). Scintimun bruges til fremstilling af en radioaktiv opløsning til indsprøjtning af 
technetium(99mTc)-besilesomab. Technetium(99mTc) er et radioaktivt grundstof, der gør det muligt at se 
de organer, hvor besilesomab ophobes, med et specielt kamera. </p>
<p>Dette lægemiddel er et radioaktivt præparat, der kun er beregnet til diagnostisk brug hos voksne. 
Efter indsprøjtning i en blodåre kan lægen få billeder (scanninger) af Deres organer, og disse billeder 
giver flere oplysninger til påvisning af steder for betændelse og/eller infektion. Scintimun må dog ikke 
anvendes til diagnosticering af diabetisk fodinfektion. </p>
<p>Brug af Scintimun medfører, at De bliver udsat for små mængder radioaktivitet. Deres læge og 
nuklearmedicineren har overvejet, om den kliniske fordel, som De vil få af undersøgelsen med det 
radioaktive lægemiddel, opvejer risikoen på grund af stråling. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Scintimun:</p>
<ul>
<li>hvis De er allergisk over for besilesomab, over for antistof fra mus eller andre antistoffer. Eller 
hvis De er allergisk over for natriumpertechnetat (99mTc)-injektionsvæske eller et af de øvrige 
indholdsstoffer i dette lægemiddel (angivet i afsnit 6). </li>
<li>hvis De har en positiv reaktion over for en prøve, der påviser antimus-antistoffer (HAMA-test). 
Spørg lægen, hvis De er usikker. </li>
<li>hvis De er gravid. </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt nuklearmedicineren, før De får Scintimun:</p>
<ul>
<li>hvis De tidligere har fået Scintimun, fordi De kun bør få indgivet Scintimun én gang i livet. 
Hvis De er ikke er sikker på, om De tidligere har fået dette lægemiddel, skal De spørge lægen. </li>
<li>hvis De har fået en skintigrafisk undersøgelse med technetium inden for de seneste 2 dage. </li>
<li>hvis De har en ondartet svulst, der udskiller et karcinoembryonisk antigen (CEA), som kan 
forstyrre denne undersøgelse. </li>
<li>hvis De har en blodsygdom. </li>
<li>hvis De ammer. </li>
</ul>
<p>Før indgivelse af Scintimun 
For at opnå billeder af bedste kvalitet og for at reducere strålingen af blæren skal De drikke rigelige 
mængder og tømme blæren før og efter scintigrafi-undersøgelsen. </p>
<p>Børn og unge 
Dette lægemiddel anbefales ikke til brug hos patienter under 18 år, idet sikkerheden og virkningen af 
lægemidlet ikke er klarlagt. </p>
<p>Brug af anden medicin sammen med Scintimun 
Fortæl det altid til nuklearmedicineren, hvis De bruger anden medicin eller har gjort det for nylig. 
Dette gælder også medicin, som ikke er købt på recept. Det skyldes, at anden medicin eventuelt kan 
forstyrre fortolkningen af billederne. 
Lægemidler, der virker mod betændelseslignende reaktioner (inflammation), og lægemidler, der 
påvirker dannelse af blodlegemer (som f.eks. glukokortikoider og antibiotika), kan påvirke resultaterne 
af undersøgelsen. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De kan være gravid, eller planlægger at blive 
gravid, skal De spørge nuklearmedicineren til råds, før De får dette lægemiddel. </p>
<p>De skal informere nuklearmedicineren inden indgivelse af Scintimun, hvis der er en mulighed for, at 
De kan være gravid, hvis en menstruation er udeblevet, eller hvis De ammer. Hvis De er i tvivl, er det 
vigtigt, at De spørger den nuklearmediciner til råds, som skal overvåge undersøgelsen. </p>
<p>Hvis De er gravid, må De ikke få Scintinun. 
Undersøgelser med nuklearmedicin kan involvere en risiko for fosteret. </p>
<p>Hvis De ammer, skal De standse amning i 3 dage efter indsprøjtningen, og den udmalkede mælk skal 
kasseres. Hvis De ønsker det, kan De udmalke og gemme mælk før indsprøjtningen. Det vil beskytte 
barnet mod den stråling, der kan være til stede i mælken. 
Spørg nuklearmedicineren, hvornår De kan genoptage amningen. 
De skal desuden undgå tæt kontakt med barnet i de første 12 timer efter indsprøjtningen. </p>
<p>Trafik-og arbejdssikkerhed 
Det er ikke sandsynligt, at Scintimun vil påvirke Deres evne til at føre motorkøretøj eller betjene 
maskiner. </p>
<p>Scintimun indeholder sorbitol og natrium 
Dette lægemiddel indeholder 2 mg sorbitol i hver hætteglas med Scintimun. Sorbitol er en kilde til 
fructose. Hvis du har arvelig fructoseintolerans (HFI), en sjalden genetisk lidelse, ma du ikke fa dette 
lagemiddel. Patienter med HFI kan ikke nedbryde fructose, hvilket kan medfore alvorlige bivirkninger. 
Inden du far dette lagemiddel, skal du fortalle din lage, hvis du har HFI. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. hætteglas, dvs. det er i det 
væsentlige natrium-frit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der er strenge lovkrav vedrørende brug, håndtering og bortskaffelse af radioaktive lægemidler. 
Scintimun vil kun blive brugt i særlige, kontrollerede områder, og præparatet vil kun blive håndteret 
og givet til Dem af personale, der er trænet og kvalificeret i at bruge det sikkert. Dette personale vil 
være særligt omhyggelig med sikker brug af dette præparat og vil informere Dem under 
undersøgelsen. </p>
<p>Den nuklearmediciner, der overvåger undersøgelsen, afgør, hvilken mængde technetium (99mTc)-
besilesomab der skal bruges i undersøgelsen af Dem. Det vil være den mindst mulige mængde, der er 
nødvendig for at få den ønskede information.<br />
Den mængde, der sædvanligvis anbefales indgivet til en voksen, ligger i intervallet fra 400 til 
800 MBq (millioner Becquerel, som er den enhed, der anvendes til at udtrykke radioaktivitet).  </p>
<p>Indgivelse af Scintimun og undersøgelsens udførelse 
Scintimun indsprøjtes i en blodåre (vene). 
En enkelt indsprøjtning i en vene i armen er tilstrækkelig til udføre den test, som lægen har brug for. </p>
<p>Undersøgelsens varighed 
Nuklearmedicineren vil informere Dem om, hvor længe undersøgelsen sædvanligvis varer. </p>
<p>Efter indgivelse af Scintimun 
Da De muligvis kan afgive stråling, der især er skadelig for små børn , i løbet af de første 12 timer 
efter indsprøjtningen, skal De undgå tæt kontakt med små børn og gravide kvinder i denne periode. </p>
<p>Nuklearmedicineren vil informere Dem, hvis De skal tage nogen særlige forholdsregler, efter at De har 
fået dette lægemiddel. Kontakt nuklearmedicineren, hvis De har nogen spørgsmål. </p>
<p>Hvis De har fået for meget Scintimun 
En overdosis er usandsynlig, eftersom indsprøjtning forberedes som en enkelt dosis af 
hospitalspersonalet under strengt kontrollerede forhold. Men i tilfælde af en overdosis vil De blive 
bedt om at drikke store mængder vand og tage afføringsmidler for at øge udskillelsen af præparatet fra 
kroppen. </p>
<p>Spørg den nuklearmediciner, der overvåger undersøgelsen, hvis De har yderligere spørgsmål om 
brugen af Scintimun. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Dette radioaktive præparat vil afgive lave mængder ioniserende stråling, der forbindes med den laveste 
risiko for cancer og arvelige abnormiteter. </p>
<p>Ca. 14 ud af 100 patienter, der har fået denne indsprøjtning, har fået påvist, at de producerer antistoffer 
i blodet, der reagerer mod det antistof, der er i Scintimun. Dette kan forøge risikoen for allergiske 
reaktioner i tilfælde af gentagen indsprøjtning af Scintimun. Derfor skal De kun have Scintimun én 
gang. 
I tilfælde af en allergisk reaktion vil De modtage relevant behandling af lægen. </p>
<p>Mulige bivirkninger er anført herunder, ordnet efter hyppighed: </p>
<p>Meget almindelig (kan påvirke mere end 1 ud af 10 personer): 
Udvikling af humane antimus-antistoffer, der reagerer mod antistoffet i Scintimun (antistof fra 
museceller) med en risiko for allergisk reaktion </p>
<p>Almindelig (kan påvirke op til 1 ud af 10 personer): 
Lavt blodtryk </p>
<p>Ikke almindelig (kan påvirke op til 1 ud af 100 personer): 
Allergisk reaktion, herunder opsvulmen af ansigtet, nældefeber (urticaria) </p>
<p>Sjælden (kan påvirke op til 1 ud af 1.000 personer): </p>
<ul>
<li>
<p>Alvorlig, allergisk reaktion, der giver åndedrætsbesvær eller svimmelhed </p>
</li>
<li>
<p>Muskel- eller ledsmerter </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller speciallægen i nuklearmedicin. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store scintimun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store scintimun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>De får ikke brug for at opbevare dette lægemiddel. Det er speciallægens ansvar at opbevare dette 
lægemiddel under egnede forhold. Opbevaring af radioaktive lægemidler vil ske i overensstemmelse 
med nationale retningslinjer vedrørende radioaktive materialer. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Scintimun indeholder 
- Aktivt stof:  besilesomab (antigranulocyt-monoklonalt antistof fra mus).<br />
En hætteglas med Scintimun indeholder 1 mg besilesomab. 
- Øvrige indholdsstoffer: (Se afsnit 2 " Scintimun indeholder sorbitol og natrium") </p>
<p>Scintimun </p>
<p>Natriumdihydrogenphosphat, vandfrit </p>
<p>Dinatriumhydrogenphosphat, vandfrit </p>
<p>Sorbitol E 
Under nitrogenatmosfære </p>
<p>Opløsningsmiddel for Scintimun </p>
<p>Tetranatriumpropantetraphosphonatdihydrat (PTP) </p>
<p>Stannochloriddihydrat </p>
<p>Natriumhydroxid / saltsyre  </p>
<p>Nitrogen </p>
<p>Udseende og pakningsstørrelser 
Scintimun er et sæt til undersøgelse med radioaktivt stof. 
Hætteglasset med Scintimun indeholder et hvidt pulver<br />
Hætteglasset med opløsningsmiddel til Scintimun indeholder et hvidt pulver. </p>
<p>Kittet indeholder én eller to multidosis-hætteglas med Scintimun med ét eller to hætteglas med 
opløsningsmiddel. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaveren af markedsføringstilladelsen og fremstiller 
CIS bio international 
B.P. F-91192 Gif-sur-Yvette Cedex<br />
Frankrig </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/.  </p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale: 
Det fuldstændige produktresumé for Scintimun medfølger som et afriveligt afsnit sidst i den trykte 
indlægsseddel i pakningen med det formål at give sundhedspersonalet yderligere videnskabelig og 
praktisk information om administation og brug af dette radioaktive præparat. 
Der henvises til produktresuméet.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for scintimun Package Leaflet for language en"
Description: "ePI document Bundle for scintimun Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3a63bcdb9de3ae0f0c08bbb2137c5dc9"
* entry[0].resource = composition-en-3a63bcdb9de3ae0f0c08bbb2137c5dc9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3a63bcdb9de3ae0f0c08bbb2137c5dc9"
* entry[=].resource = mp3a63bcdb9de3ae0f0c08bbb2137c5dc9
                            
                    
Instance: bundlepackageleaflet-da-3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for scintimun Package Leaflet for language da"
Description: "ePI document Bundle for scintimun Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3a63bcdb9de3ae0f0c08bbb2137c5dc9"
* entry[0].resource = composition-da-3a63bcdb9de3ae0f0c08bbb2137c5dc9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3a63bcdb9de3ae0f0c08bbb2137c5dc9"
* entry[=].resource = mp3a63bcdb9de3ae0f0c08bbb2137c5dc9
                            
                    



Instance: mp3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product scintimun"
Description: "scintimun"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/602/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "This medicinal product is for diagnostic use only."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "scintimun"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 3a63bcdb9de3ae0f0c08bbb2137c5dc9ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "scintimun"

* status = #current
* mode = #working

* title = "List of all ePIs associated with scintimun"

* subject = Reference(mpa9ec64f13568156fa1a6ff3b0e61aebc)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#scintimun "scintimun"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3a63bcdb9de3ae0f0c08bbb2137c5dc9) // scintimun en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3a63bcdb9de3ae0f0c08bbb2137c5dc9) // scintimun da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3a63bcdb9de3ae0f0c08bbb2137c5dc9
InstanceOf: List

* insert 3a63bcdb9de3ae0f0c08bbb2137c5dc9ListRuleset
    